At Terremoto, we are creating a seismic shift in the breadth of pursuable targets. Our ultimate goal? To deliver highly targeted, small molecule medicines with optimized clinical profiles and superior therapeutic benefit.

Our Story

Breaking Open the Covalent Drug Universe

The world has witnessed incredible advances in drug development over the last two decades, including new drugs for previously intractable targets. And yet, many patients still face too few treatment options, notably in devastating conditions like cancer.

Enter covalent chemistry.

At Terremoto, we are breaking open the covalent drug universe with the power of lysine-targeted chemistry. In harnessing lysine-based covalency across the disease spectrum, we are focused on developing both best-in-class therapies against known drug targets and first-in-class medicines against the previously undruggable. Our founders helped create this emergent area of science, enabling our team of world-class chemists, biologists and drug developers to pursue a well-defined platform approach and translate treatments to patients as quickly as possible.

We view ourselves as champions for patients. The ultimate driving force behind our work is bringing highly effective medicines to people with devastating diseases as quickly as we possibly can.

The Earth-Shakers

Founded by the Pioneers

With the deep knowledge of our founders, leadership and overall team, we have the ability to translate our ambitious vision into real treatments. Most importantly, our group has set the industry standard for rapidly delivering these medicines to patients – a record we intend to maintain with our platform approach.

Peter Thompson, M.D.

Co-founder and CEO

Brian Bestvater

Associate Scientist, Chemistry

Patrick Brassil, Ph.D.

Vice President, Pharmacology

Jordan Carelli, Ph.D.

Director, Biology

Garrett Chado, Ph.D.

Associate Director, Formulation

Regina Choy, Ph.D.

Director, Biology

Chvon Christy

Buyer/Planner, Finance

Hang Chu, Ph.D.

Executive Director, Medicinal Chemistry

Bryan Cox, Ph.D.

Sr Director, Computational Chemistry

Brittany Coyne

Associate Scientist, Biology

Janaina Dargell

Sr Manager, HR

Subhamoy Das, Ph.D.

Sr Scientist, Biology

Rebecca Freilich, Ph.D.

Sr Scientist, Biology

Vivian Ho

Sr Director, Finance and Accounting

Karin Ku

Sr Scientist, Biology

Rusty Lipford, Ph.D.

Sr Vice President, Biology

Grace Lu

Vice President, Business Development

Charlie Ma, Ph.D.

Sr Director, Structural Biology

Andrea Orozco

Executive Assistant, Office Manager

Solomon Reisberg, Ph.D.

Executive Director, Medicinal Chemistry

Andrey Rymar

Associate Scientist, Biology

Jacob Schrier, Ph.D.

Sr Scientist, Biology

Michael Schulte, Ph.D.

Sr Scientist 2, Biology

Wayne Spevak, Ph.D.

Sr Vice President, Chemistry

Jessica Sun, Ph.D.

Sr Director, Head of In Vivo Pharmacology

Saba Tamjidi

Sr Associate Scientist, Biology

Melissa Wong

Sr Research Associate, Biology

Kin Yang, Ph.D.

Executive Director, Medicinal Chemistry

Adam Zajdlik

Scientist, Chemistry

Board of Directors

Charles Baum, M.D., Ph.D.

President, Founder and Head of
Research and Development, Mirati

Reid Huber, Ph.D.

Partner, Third Rock Ventures Director

Kevin Koch, Ph.D.

President, CEO and CFO, Edgewise
Venture Partner, OrbiMed

Jack Taunton, Ph.D.

Professor, Cellular Molecular
Pharmacology, UCSF

Peter Thompson, M.D.

Co-founder and CEO, Terremoto
General Partner, OrbiMed

Jeff Tong, Ph.D.

Partner, Third Rock Ventures Director


Matthew Jacobson, Ph.D.

Co-founder, Terremoto
Professor and Chair in the Dept. of
Pharmaceutical Chemistry, UCSF

Jack Taunton, Ph.D.

Co-founder, Terremoto
Professor, Cellular Molecular
Pharmacology, UCSF

Peter Thompson, M.D.

Co-founder and CEO, Terremoto
General Partner, OrbiMed Founder